A small, under-the-radar pharmaceuticals pioneer has brought America's most dreaded disease to its knees...
Gains of 30-60 times your money or MORE are all but certain if you're holding shares when Big Pharma buys it out - which could happen any day now!
Dear Friend,
Usually, medicine advances only in small steps. A less invasive form of surgery. A refinement to a medication that reduces its side effects. A minor advancement in materials for prosthetics or artificial cartilage...
Rarely do big and truly significant medical breakthroughs happen.
But rarer still do they happen under the radar to the extent that everyday investors with the right info can get money down on the breakthrough plays - before they become headline fodder and the target of "in-the-know" money from around the world.
However, such a rare window of opportunity exists RIGHT NOW.
If you're willing to spend five minutes to read this bulletin now - and consider investing even a small amount of money in the breakthrough micro-pharma that's about to run the table on one of today's most feared "incurable" diseases - you could easily be sitting on 3,000-6,000% gains or MORE on your money in a stunningly short amount of time...
IF you beat Big Pharma to the punch.
You'll have to move fast, because right now, virtually the entire pharmaceuticals industry is licking its chops over this $6-per-share small cap like it's a medallion of filet mignon mistakenly served in an all-you-can-eat buffet of Steak-umms and soy burgers...
Big Pharma buys out 2 kinds of companies:
those that can give it a competitive advantage
and those that can take its away
This one's both
Earlier this year, a small American pharmaceuticals company was formed through a "reverse merger" - a process that creatively sidesteps cumbersome and time-consuming SEC rules regulating how a firm goes public with its stock...
Here's why this crafty maneuver is key:
It enables this pioneering company to quickly bring to market its breakthrough developments, instead of wading through the SEC's laborious process (which is especially convoluted for drug companies).
These "quantum leap" advancements in pharmaceutical technology were made possible by the firm's exclusive rights to no less than six patents generated by research conducted by the renowned Mayo Clinic...
Those patents isolate and protect a powerful chemical compound that's virtually free of side effects and at least eight times more effective than some other treatments at combating - and maybe even reversing - one of today's most dreaded diseases: Alzheimer's.
These pedigreed patents are the reason why...
Big Pharma's biggest players are waving blank
checks at this fledgling drug firm - and at YOU,
if you're holding shares
This new company's Alzheimer's drug sailed through FDA Phase 2 drug trials with flying colors - spurring immediate interest in either a licensing agreement or an outright buyout from one household-name drug giant.
Wisely, the company hasn't accepted. Yet.
And that's lucky news for you...
Because according to the best emerging technology analyst I know (you'll agree after you meet him in a minute)...
This offer is all but certain to soon spark a
bidding war among the giants of the world's
most profitable business
That's why you have to get in on this stock NOW if you want a chance at 3,000%, 4,000%, even 6,000% gains or more practically overnight in this impending bidding war.
The odds are excellent that in the near future (perhaps the very near future, if the results of the FDA's clinical trials are any indication) Pfizer, Novartis, Forest or one of the drug industry's other deep-pocketed giants will pony up the billions it'll surely take to make the deal for this micro-pharma pioneer - and send your shares into the stratosphere of 30, 40, even 60 times your money or more...
They really don't have a choice, either.
If one of Big Pharma's mammoth players doesn't scoop up this firm and its patents, they'll ALL risk being rendered that much closer to obsolete by this little company's incredible treatment for one of America's most dreaded diseases.
And that disease has a multibillion-dollar market that's only getting bigger as the baby boomers crest middle age and enter their twilight years...
This overlooked killer could lead you to killer profits
in an investment that feels good - and pays good, too...
When people think of the leading causes of death in the U.S., they think of heart disease, cancer, diabetes, stroke, etc...
They probably don't think of Alzheimer's disease. Yet despite being somewhat under the radar, dementia-related conditions are arguably the third leading cause of death in America. And with the baby boomers now reaching prime age for Alzheimer's vulnerability, that rank will likely climb even higher. Here's why this is important (and urgent) to you:
In 2005 alone, Americans spent nearly $2 billion on Alzheimer's drugs. By 2010, that number is estimated to be closer to $5 billion per year.
That's just in the U.S., remember.
To put that in the proper perspective for your impending profits, the combined GLOBAL take for BOTH of the leading impotence drugs - Viagra and Levitra - was only $2.5 billion in 2004, and that's with the strength of more than half a billion dollars in advertising behind them...
See how big a market there is for Alzheimer's medications? It's tragic, but it's the reality. And here's the kicker: Modern Alzheimer's drugs don't even work.
That's Big Pharma's dirty little dementia secret. Americans are spending billions per year on drugs for senility that:
- Don't arrest the progress of Alzheimer's in the least
- Yield measurable improvements for only 15-40% of patients
- Cause side effects so severe most can't take them for more than 6 months.
Now, if Americans are projected to spend $5 billion a year by 2010 on drugs that offer this bleak an outlook, imagine how much of these drugs the major pharmaceuticals players would sell if they DID work - if they actually stopped or even reversed the progression of Alzheimer's disease, and with no significant side effects whatsoever...
That's what this "little-pharma-that-could" company can likely offer them.
Its timing (or yours) couldn't be better, either. Keep reading...
Just discovered: 3.2 million more future
American Alzheimer's patients - and
potential dementia drug buyers
As though the aging baby boomers don't represent enough of a potential balloon market for effective Alzheimer's treatments, there's this to consider...
Researchers have just identified a precursor to dementia called mild cognitive impairment (MCI). Its subtle symptoms (anybody could mistake them for simple memory lapses) progress to full-blown Alzheimer's disease a startling 80% of the time.
Currently, at least 4 million people are afflicted with MCI in the U.S.
That means Alzheimer's is unexpectedly on the horizon for an additional 3.2 million Americans...
Unfortunate, yes.
But now there's hope for them - and everyone who's already suffering from Alzheimer's - once this micro-pharma pioneer's incredible biotechnology is bought outright or licensed by a major player of the pharmaceuticals industry. Or if the company brings it to market itself in a matter of a year or two at most...
Either way, YOU win big if you get in now
dirt-cheap - before news of this breakthrough
reaches mainstream money analysts
As you'll discover in a moment - in your FREE Special Report on this medical miracle stock and its revolutionary profit prospects (written by the only biotech analyst I trust) - this "giant killer" pharma-tech firm has an ironclad competitive advantage over other players in the industry...
An advantage YOU can cash in on - to the tune of 3,000-6,000% or more, easily. But only if you act fast, before everyone and his brother find out about this medical story-of-the-century in the making...
Bottom line: Millions of lives could soon be saved or made better by this Alzheimer's breakthrough - and many millions of dollars could rapidly be made by a savvy few investors (you could be one of them) as its potential is realized one way or another....
The question is: How big a piece of these
millions (maybe billions) of dollars in certain
profit do YOU want to make?
Once a buyout or licensing deal begins to heat up (it'll likely happen very soon), thousands of savvy investors will no doubt jump into this stock with both feet - and your window of opportunity to practically steal shares of it will be gone forever...
Along with your one chance to rake in gains of 30-60 times your money or more in less time than any other tech play I've ever seen. These are the kinds of short-term profits that would raise a seasoned venture capitalist's eyebrows!
But I'm getting a little ahead of myself here, and maybe a bit ahead of you...
Right now, you're probably asking yourself two questions: Who is this guy? And how does he know this micro-pharma stock is going to yield kingpin-sized gains over the next few years?
Fair enough. First things first.
My name is Addison Wiggin. I've made my living as a commentator and financial historian in the major media on matters financial (and political) for more than 12 years. I'm a regularly invited guest speaker at investment conferences and conventions the world over. You may recognize my name from my regular appearances on CNN, CNBC, Fox News and others...
Or from the three New York Times best-selling money titles I've written or co-authored: Financial Reckoning Day, The Demise of the Dollar and Empire of Debt. Beyond this, I'm the publisher of several financial newsletters and investment advisories, and co-author of the long-running money and markets e-letter, The Daily Reckoning (circulation 400,000)...
I tell you all of this not to beat my chest, but so that you'll believe me when I say:
Rarely before in stock market history has such a mammoth, life-changing (and fortune-making) emerging technology offered savvy investors so great a chance at rapid, extreme profit - underneath the "radar" of the money mainstream...
Now, to answer that second question. I'll do it with a confession:
I really DON'T KNOW exactly why the $6-per-share pharma-tech pioneer you're about to get rich on is poised to corner Big Pharma into shelling out a major payday to its shareholders. That's because I didn't graduate from MIT with a degree in microbiology - or whatever these guys that are on the forefront of pharmaceuticals research get their degrees in...
Of course, I know why their grossly undervalued firm is a sound one: their strong fundamentals, inspired management and generally what their competitive advantage is. But if you're asking me to explain precisely how their nature-based drug line is superior to their competitors' synthetic drugs, I'm at a loss.
But what I DO know is this:
The most brilliant technology analyst I've
ever met is utterly convinced that this firm
will go up in value 30-60 times over
According to him, this'll happen one of two ways:
First, if Big Pharma buys it out or inks a mega-dollar licensing deal with it.
Or second, it completes the final stage of FDA approval (which is all but in the bag, according to my analyst - learn why in your FREE Special Report) and stuns the entire pharmaceuticals industry with a debut drug that's instantly among the most sought-after in medicine...
That's when you'll be sitting pretty - if you get in on this future industry player at $6 A SHARE!
The genius/scientist/consultant/Renaissance man behind this analysis is Jonathan Kolber. And fortunately for you, he now writes one of the newsletters I publish, The Emerging Capital Report - which means he could soon be advising you about not only the life-changing developments, but also the hush-hush dealings of the emerging tech world that could render you richer than rich...
Like the future pharmaceuticals "kingpin" I've been telling you about.
Keep reading and in just a minute, I'll show you how to get the FREE Special Report on this incredible small-cap biotechnology profit-play I asked Jonathan to write specifically for readers like you... In the 23 years since he graduated with an MBA from the prestigious Carlson School of Management at the University of Minnesota, Jonathan Kolber has done just about everything in the technology world. He has co-founded, managed and VPed several successful technology companies between the early '80s and the late '90s. He has served as a consultant and editor on countless winning business plans for tech ventures. He has served three separate terms as president of a consulting firm specializing in emerging technology investment. He has guided his and other companies to multiple patents. And he has solicited and directed tens of millions of dollars in venture capital for his own enterprises and others'. Along the way, he has accrued vast knowledge and experience in fields such as supercomputers and software, nuclear fusion and alternative energy, advanced nutrition and pharmaceuticals, e-commerce and the Internet, robotics, genetics, AI and nanotechnology. Now he puts all of this expertise to work for one purpose: informing and enriching the readers of his newsletter, The Emerging Capital Report.
This breakthrough stock
won't be cheap for long -
your window of greatest
opportunity is closing fast
Breakthrough medical news doesn't stay quiet for long.
That's why even if an impending Big Pharma buyout of this small-cap pioneer weren't poised to happen soon, the stock price would still likely zoom upward - starting any day now. Once news of any REAL advancement in treatment for disease (especially a major, scary one like Alzheimer's) comes down the pike, related stocks move on the news alone...
In other words: By the time you read about it in USA Today, it's too late to make the major money.
That's why to get you invested before this breakthrough makes the headlines (it'll happen soon, most likely), I asked Jonathan to write a Special Report on this once-in-a-lifetime pharma-tech profit-play...
It's called The Kingpin Drug Stock: 3,000-6,000% Profits as a Killer Is Brought to Its Knees. In it, you'll learn all the details about this company:
- How its technology works - and what it means for modern life
- Why this firm's technology will bring Big Pharma to heel
- What makes it better (and likely more profitable) than its competitors
- Who is running the firm - and why they're the best at what they do
- Where they're going to sell their innovative technology for unreal money
- When this company will begin to make you rich if you're in on it (it'll be sooner than you might imagine)...
This in-depth Special Report is yours FREE below. Keep reading. But right now, I want to tell you why...
Even if this company never sells a single pill
or gets one red cent from Big Pharma, it'll
still likely go up 10 times in value...
What are some of the safest investments you can make?
Those that are backed by the U.S. government - things like bonds and T-bills.
Well, this small-cap pharma-tech firm may also soon enjoy this same kind of security and governmental protection. Sort of...
That's because its patented, proprietary breakthrough for Alzheimer's also may provide protection against deadly nerve gas.
Space doesn't permit me to go into all the details here, but in your FREE copy of The Kingpin Drug Stock: 3,000-6,000% Profits as a Killer Is Brought to Its Knees, you'll learn how this firm has been working under a Cooperative Research and Development Agreement with the Army's Walter Reed Medical Center...
The fruits of that agreement:
That after FDA approval, the U.S. military and/or the Department of Homeland Security could very likely opt to license this breakthrough compound for troop inoculation or stockpiling in the event of terrorist attacks with chemical weapons.
Such a deal with the government would likely make this stock go up in value AT LEAST 10 times over - which is exactly what the "in-the-know" analyst I depend on is predicting will soon happen. Want to learn a bit more about him? Keep reading...
Meet the only man I trust for the real scoop
on technologies investors can make 20, 50,
even 100 times their money on
For more than 20 years, Jonathan Kolber has lived and breathed technology...
And not just as an analyst. He's been a hands-on pioneer in various technological ventures, some of them life-changing products and services you may have even used yourself - like try-before-you-buy computer software, and those limited-use DVD movies available at places like 7-Eleven, Papa John's and other national chains, just to name a few...
Here's why that's important: Because he's been a winner in the tech trenches himself, Kolber has seen a lot of technologies come and go over the last two decades. More than anyone else I've ever met, this fact qualifies him to know the ones with the ability to transform our lives from the ones that are simply fads - or flops.
Beyond this, Jonathan's got the connections mere journalists don't
And they all TALK to him. Plus, he attends just about every cutting-edge technology conference and gathering in the free world, no matter how obscure. That's how he discovers companies like the electro-tech micro-player I've been crowing about since the start of this bulletin.
That's why two years ago, I hired him away from his latest technology venture to be the editor of The Emerging Capital Report investment advisory - to transition from developing new transformational technologies to alerting investors about them.
Now, instead of focusing on just the one segment of the technology market he's trying to compete in (or to pioneer), Jonathan is focused on the entire spectrum of the emerging technology world. This perspective allows him to think three, four, even 10 moves ahead - like a grandmaster in the tech investing chess game.
From his new vantage point as an investment adviser, he gets to see the entire game board of tech industry trends and opportunities that open the door for profits that are bordering on obscene - like the small U.S. pharma-technology player I mentioned earlier that's about to become the "kingpin" of the pharmaceutical industry...
I'm talking about venture capitalist-type gains of 20, 50, even 100 times your money or more.
Enough to turn just a few thousand bucks into enough money to retire with - on your own private island. The company I've been telling you about is just one of the dozens Jonathan has alerted his readers to, some of which have already gained over 1,000% in value...